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Background/aim: We aimed to evaluate the association of the umbilical cord macrophage migration inhibitory factor (MIF) with the
respiratory distress syndrome (RDS) in preterm infants.
Materials and methods: A total of eighty six preterm infants (38 with RDS and 48 without RDS) were involved in the study. ELISA is
the technique assaying MIF values. Results: The mean of the infants’ gestational ages and birth weights were significantly different (P
= 0.0001). There were no significant differences in sex, delivery mode or exposure to antenatal steroid among the groups (P > 0.05).
Umbilical cord MIF levels of the infants were not correlated with gestational age and birth weight (Spearman’s rho = –0.22 and 0.28
respectively, P > 0.05). There was no statistically significant difference in umbilical cord MIF levels of infants whether or not they were
administered antenatal steroid (median:17.88 vs. median:17.60, Mann–Whitney U test, P = 0.42). Cord serum MIF levels were higher
(mean, 17.09 ± 5.86 ng/mL) in the RDS group than in the non-RDS group (mean, 14.72 ± 4.18 ng/mL) (P = 0.005).
Conclusion: This study shows that, MIF level is higher in the cord blood of the infants with RDS than of the infants without RDS. This
supports that MIF expression begins in prior to the birth of the preterm infants and MIF has enhancing impact on the lung development
of premature babies. With future studies, the assessment of the cord MIF levels at the bedside may be beneficial for the diagnosis and
treatment of RDS, and taking actions to prevent long-term consequences.
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1. Introduction
Respiratory distress syndrome (RDS) is the most common
respiratory complication of premature infants in early life
[1–5]. Main causes of RDS are underdevelopment of the
lung and lack of surfactant synthesis [1–3]. Even the low
birth weight (BW) and the low gestational age (GA) increase the risk of RDS, these factors alone are not enough
for a prediction regarding to the development of the disease [2,3]. Identifying the molecular parameters that cause
RDS and bronchopulmonary dysplasia (BPD) will lead
breakthrough improvements in the treatment process
[2,3,5].
Macrophage migration inhibitory factor (MIF) is a
primary immune response regulator that has a role in the
development of serious diseases, such as acute respiratory
distress syndrome (ARDS), asthma, cancer and autoimmune disorders [6–12]. MIF has a devastating role in adult
ARDS [10,11]. In literature search, there is only one human study about the effect of MIF on the developmental
lung diseases in newborn infants [13].

It was aimed to determine the differences of MIF values in the cord blood of the preterm babies with RDS and
non-RDS, and to assess whether the MIF may be a diagnostic marker for RDS in the light of future studies.
2. Materials and methods
This prospective cross sectional study was conducted in a
tertiary neonatal intensive care unit (NICU) of Bezmiâlem
Vakıf University Hospital between July 2012 and June
2013. Since the cord blood was used, only inborn infants
were included in the study.
2.1. Patients
The groups were allocated into two by selecting the infants
of GAs between 24 and 34 weeks. Exclusion criteria for
the study were listed as: (i) infants with early onset neonatal sepsis or congenital anomalies or small for gestational
age, (ii) infants who had mothers with diabetes mellitus
or gestational diabetes mellitus, (iii) mothers with a history of chronic diseases such as renal failure, autoimmune
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diseases or hypertension, (iv) mothers who had preterm
premature rupture of membranes (PPROM) longer than
48 h or had chorioamnionitis.
Group 1, included thirty-eight infants, who were diagnosed with RDS according to the clinical signs and the
radiological findings. Forty-eight infants were in group 2,
who had non-RDS. Six infants whose cord blood samples
were not taken, two infants with Down syndrome and one
infant with complex congenital heart defect were excluded from the study.
The following data were collected: BW, GA, sex, delivery mode, exposure to the steroids before the birth, the
days on the respiratory support and the oxygen supplementation, and presence of BPD and the other complications of preterm birth. BPD was determined according to
the guidelines [3].
2.2. Measurement of serum MIF levels
Umbilical cord blood samples (10 mL) from all premature
infants were drawn into a tube under sterile conditions.
The samples were taken from the umbilical cord just after the birth. It needs to be noted that the delayed cord
clamping procedure was not a practice of obstetricians
at the time of the study. The sample tubes were placed
in ice packs and delivered to the laboratory according to
the cold chain rules. Then, the umbilical cord blood was
centrifuged at 4.500 rpm, and the serum was taken into
Eppendorf tubes. The samples were kept in the –80 °C
freezer until the working day. The samples were analysed
with ELISA via MIF kit (Quantikine, R&D Systems, Inc.,
Minneapolis, MN, USA) (catalogue number DMF00B;
R&D Systems, Inc.). MIF concentration was mentioned
between 15.3 and 52.3 ng/mL by the manufacturer.
2.3. Statistical analysis
To analyse the data, SPSS software (version 18.0; SPSS Inc.,
Chicago, IL, USA) was performed. The sample distribution was tested by Kolmogorov–Smirnov considering the
GA, BW and umbilical cord MIF values. Normally distributed variables were compared by t-test and expressed
as the mean ± standard deviation. The categorical variables were analysed with chi-square test. The comparison
of MIF values in the cord blood that were not normally
distributed, was determined using the Mann–Whitney U
test. The relations of GA and BW with MIF values were
shown by Spearman’s correlation test. A P-value lower
than 0.05 was noted statistically significant.
3. Results
The clinical characteristics of both groups were presented
in Table 1. The mean of GA, BW, and duration of mechanical ventilation, noninvasive ventilation and oxygen
use were significantly different between the infants with
RDS and non-RDS (P values; 0.0001, 0.0001, 0.01, 0.004,
0.003, respectively). BW and GA were significantly lower

Table 1. Demographic characteristics of preterm infants.
Variable

Infants without
RDS (n = 48)

Infants with
P value
RDS (n = 38)

Gestational age
(week)

33.40 ± 1.87

29.79 ± 3.51

22 (45.83)

1353.68 ±
508.09
23 (60.53)

25 (52.10)

18 (47.40)

NS

32 (66.67)

31 (81.58)

NS

7 (4–9)

6 (1–9)

0.004

8 (5–9)

0.001

0.85 ± 5.09

8.50 ± 20.39

0.01

1.64 ± 3.71

6.39 ± 10.20

0.004

3.94 ± 9.29

20.55 ± 35.61 0.003

Birth weight (gram) 1981.98 ± 420.12
Sex (Male)
Antenatal steroid
exposure
Delivery mode
(caesarean section)
Apgar score, 1min,
median (range)
Apgar score, 5 min,
median (range)
Mechanical
ventilation (day)
Noninvasive
ventilation (day)
Oxygen use (day)

0.0001

8.5 (6–10)

0.0001
NS

RDS, respiratory distress syndrome; P < 0.05, statistically
significant; NS, not significant.
Values are expressed as n (%) or as the mean ± SD.

in infants with RDS than in those without RDS. Sex, delivery mode or antenatal steroid (ANS) exposure showed no
significant differences between the groups (P > 0.05). The
causes for the preterm birth were detected as unknown
reason (48.8%), preeclampsia (24.4%), cervical insufficiency (15.1%), PPROM (<48 h) (8.1%), placenta previa
(3.6%). Antibiotics were given to mothers who experienced PPROM (n = 7).
Cord MIF levels were higher (P = 0.005) in the RDS
group (mean, 17.09 ± 5.86 ng/mL) than in the non-RDS
group (mean, 14.72 ± 4.18 ng/mL) (Figure). MIF levels
were not correlated with GA or BW (Spearman’s rho =
–0.22 and 0.28 respectively; P > 0.05, Table 2). There was
no statistically significant difference in umbilical cord MIF
levels of infants whether or not they were administered
ANS (median: 17.88 vs. median: 17.60, Mann–Whitney U
test, P = 0.42). Considering to the delivery mode and cord
MIF levels, we found statistically significant difference
between groups of the caesarean section and the vaginal
delivery (median: 18.21 and median: 11.91 respectively,
Mann–Whitney U test, P = 0.000). The relationship between BPD and MIF values was not evaluated in this study.
In our study, we diagnosed BPD only in eight infants. Six
infants died before 36 weeks of postconceptional age so
they were not evaluated for BPD.
According to clinical follow up of our study groups, five
(5.8%) babies had necrotizing enterocolitis, ten (11.6%)
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Figure. Cord blood MIF levels in preterm infants with and without respiratory
distress syndrome.
Table 2. Correlation between gestational age, birth weight and
MIF levels.
Variables (n = 86)

MIF

P

GA (r*)

–0.22

0.13**

BW (r*)

–0.28

0.06**

*Spearman’s rho.
**Spearman correlation test; r, Spearman’s rho.
MIF, macrophage migration inhibitory factor; GA, gestational
age; BW, birth weight.

had patent ductus arteriosus, six (7.0%) had intraventricular haemorrhage. Of the 68 patients whose ophthalmologic screening were done, 16 (23.5%) infants had retinopathy
of prematurity.
4. Discussion
This study assessed that the cord MIF levels were higher
in infants with RDS than in infants with non-RDS. It was
emphasized that MIF could be detected in the cord blood
and might be used in the early diagnosis of RDS. RDS is
a multifactorial disease that involves polymorphisms of
genes functioning in the lung development, the alveolar
stability and the pulmonary host defence [2]. Although the
major causes of RDS are undeveloped peripheral airways
and lack of surfactant, the mechanisms of tissue injury
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have not been clarified [4]. Many factors impair respiratory adaptation and delay recovery from RDS [2].
MIF has a diurnal rhythm, which suggests the neuroendocrine control and it ranges between 2 and 10 ng/mL
in human blood [7]. MIF has been found in serum, urine,
amniotic fluid, human milk and cord blood [13–15]. It was
known that MIF is secreted more rapidly in comparison to
other proinflammatory mediators such as IL-1, IL-6, IL-8
and tumor necrosis factor-α (TNF-α) [15]. Therefore, the
studies have focussed on the pregnancy, the labor and the
infants to identify the pathogenesis of abnormal conditions
[13,15]. However, the trials that measured the cord MIF
levels were scarce. The cord blood MIF levels were found
higher than maternal serum MIF levels in vaginal deliveries in term neonates [15]. We observed that the cord blood
MIF levels were significantly higher in caesarean delivery
than vaginal delivery in preterm infants. In another study,
the peripheral blood level of MIF was markedly increased
in the first day of life in the premature infants nevertheless they did not found any correlation between MIF levels
and GA [13]. We found that there were no statistically significant differences in the MIF levels between infants with
GAs 24–29 weeks and those with GAs 30–34 weeks (not
shown). We also did not find any significant difference between ANS exposure and MIF levels in our study.
MIF has pleiotropic traits that play a main role in
various inflammatory diseases as well as in cancer [6–9].

BAYRAKTAR et al. / Turk J Med Sci
Blood MIF concentrations can be elevated to extremely
high levels in the inflammatory diseases [8,9]. Furthermore, MIF has been involved in the pathogenesis of sepsis,
asthma, cystic fibrosis, metabolic diseases [8–10,16–19].
MIF favours the innate immune response [17]. Downregulation of MIF is a proposed therapeutic option in MIFrelated disorders [16]. Calandra et al. found that MIF was
in a high concentrations in septic patients [16,17]. MIF
involves in embryogenesis and in parturition [20,21]. The
roles and functions of MIF in neonates are not well known
[22]. There are limited articles about MIF in neonates
[13,23,24]. The MIF levels are increased in the acute stage
of necrotising enterocolitis in premature babies [23].
Alveolar macrophages, bronchial epithelial cells, alveolar endothelial cells, monocytes and eosinophils expresses
the MIF in lungs [11–13]. MIF seems to take a part in inflammatory lung disease [11,12]. MIF also regulated the
angiogenesis [16]. The patients with ARDS had high levels
of MIF in bronchoalveolar lavage [10,11]. The convincing
evidence on the effective role of MIF in the pathophysiology of developmental neonatal lung diseases are limited [13,24]. MIF controlled the production of other cytokines such as IL-1β, IL-6, IL-8 and TNF-α in neonatal
lung diseases [16]. It was shown that MIF played a role
in lung maturation in animal studies. Prematurely born
MIF-deficient mice had severe respiratory distress and
mortality was high in this group [12]. It has been shown
that MIF increases the expression of surfactant protein B
from epithelial type II cells in the alveoli [16]. Prencipe et
al. [13] found high serum MIF levels in preterm neonates
with RDS on day 1 after birth. Taken together, these studies conclude that MIF is effective and protective factor in
lung maturation in preterm infants [12,13]. The present
study also contributes to the literature by finding high cord
blood MIF levels in preterm infants with RDS just before
breathing. Our outcomes support the studies that noted
increased expression of MIF before and after breathing
[13]. Thomas et al. [24] showed that MIF in tracheobronchial aspirate fluid was the highest in the first 24 h after
birth in the extremely premature infants. Our findings also
suggest that releasing of MIF is starting in the antenatal
period. Whether the cord values reflect lung concentrations remains to be established.
According to the European guidelines, the early surfactant therapy is better than the late surfactant therapy
in terms of the complications [1]. Today, the diagnosis of
RDS can only be determined by clinical signs, using chest
X-ray and failure of continuous positive airway pressure.
In practice, this causes confusion for neonatologists. The
efficacy of detecting surfactant in gastric aspirates is being

tested [1]. Future work which will define the cut-off MIF
values of patients with RDS can be useful to get a clue RDS
development at bedside after birth. Thus, the surfactant
can be given without clinical deterioration and the patient
can be protected from the invasive interventions and the
respiratory complications as well as BPD. Clinicians can
also avoid the late diagnosis or giving unnecessary surfactant.
Our study also has some limitations. Firstly, we only
measured the cord blood MIF so we could not compare
such levels with those in peripheral blood. Secondly, a
genetic investigation could not done, such as the studies
of the MIF-173 SNP. Thirdly, even the MIF stimulates the
expression of many proinflammatory cytokines just as IL6, IL-8, TNF-α, the investigation on any of them could be
held due to the financial issues. In fourth, the MIF values
after surfactant therapy could not be studied to show the
prolonged inflammatory response. In fifth, BPD was not
evaluated in this study as the extremely preterm babies
were not common. Lastly, the present study was not able
to show that the cord levels of MIF reflect on the lung concentrations.
In conclusion, this study suggests that the MIF level is
higher in the cord blood in infants suffering from RDS.
This supports that MIF starts to release in intrauterine life
period and MIF is an important factor to improve lung
development of premature infants. With future studies,
identifying the cut off values of MIF in RDS, and the assessment of the cord MIF levels at the bedside could be
useful to manage the proper treatment in a timely manner and to prevent RDS and its long term consequences by
taking precautions.
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